Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jul;58(7):715-21.
doi: 10.1136/jcp.2004.020123.

The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status

Affiliations

The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status

D Sahni et al. J Clin Pathol. 2005 Jul.

Abstract

Background: Sentinel node (SN) status is the most important prognostic indicator in patients with cutaneous melanoma without clinically evident metastatic spread, but the procedure is associated with considerable morbidity. The LYVE-1 lymphatic marker offers the possibility of studying lymphangiogenesis and tumour metastasis within the primary excision.

Aims: To establish whether lymphatic vessel numbers/distribution within the primary tumour correlated with SN status. To assess whether tumour cells were easily demonstrable within lymphatics and could be used as a surrogate for SN status.

Methods: Double immunostaining for LYVE-1 and S100 in cutaneous biopsies from 18 SN+ patients with no lymphatic/vascular involvement on routine histology and 18 SN- patients matched for tumour thickness and ulceration.

Results: Lymphatic vessels were detected in all cases. Vessels within the tumour mass were suggestive of active lymphangiogenesis; those outside were mainly mature vessels with well defined walls. Tumour cells within lymphatics were detected in one of 18 SN- and five of 18 SN+ patients. Lymphatics containing tumour cells were all outside the tumour mass in well formed vessels, suggesting melanoma cell invasion into preformed lymphatics. There was no significant difference in lymphatic counts between SN+ and SN- patients. Although peritumorous lymphatic counts were higher in ulcerated than non-ulcerated melanomas, they did not vary with Breslow thickness.

Conclusion: LYVE-1 staining can reliably demonstrate lymphatic vessel distribution, but lymphatic counts cannot predict melanoma metastatic potential and cannot substitute for SN biopsy. LYVE-1 immunostaining can detect melanoma cells within lymphatics, but is unreliable in predicting melanoma metastasis, failing to detect metastatic spread in more than two thirds of patients with regional node metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Section of mature intertumorous lymphatic vessels stained with LYVE-1/S100 demonstrating well defined endothelial cells and a well formed lumen, devoid of blood cells. Note the four adjacent unstained blood vessels. (LYVE-1 stains red; S100 stains brown; original magnification, ×40).
Figure 2
Figure 2
Section of an immature LYVE-1 positive lymphatic vessel within the tumour mass displaying a typical fibrillary pattern (LYVE-1/S100 stained section; LYVE-1 stains red; S100 stains brown; original magnification, ×100).
Figure 3
Figure 3
Section showing individual dermal cells staining positively with LYVE-1. Note the mature LYVE-1 positive peritumorous lymphatic vessel and the adjacent unstained blood vessel. An S100 positive nerve bundle is present at the lower right pole (LYVE-1/S100 stained section; LYVE-1 stains red; S100 stains brown; original magnification, ×80).
Figure 4
Figure 4
Comparison of peritumorous lymphatic counts (open circles) and tumorous lymphatic counts (closed circles). SNP, sentinel node positive; SNN, sentinel node negative; U, ulcerated; NU, non-ulcerated; ⩽2/>2, Breslow thickness (mm).
Figure 5
Figure 5
Comparison of intertumorous and peritumorous lymphatic counts combined (open circles) with intratumorous lymphatic counts (closed circles). SNP, sentinel node positive; SNN, sentinel node negative; U, ulcerated; NU, non-ulcerated; ⩽ 2/>2, Breslow thickness (mm).
Figure 6
Figure 6
(A) LYVE-1/S100 stained section showing a cluster of melanoma cells within a LYVE-1 positive peritumorous lymphatic vessel (LYVE-1 stains red; S100 stains brown; original magnification, ×60). (B) A tumour embolus is present but less apparent in a serial section stained with haematoxylin and eosin (original magnification, ×60).
Figure 7
Figure 7
LYVE-1/S100 stained section showing a single melanoma cell within a LYVE-1 positive lymphatic vessel (LYVE-1 stains red; S100 stains brown; original magnification, ×100).
Figure 8
Figure 8
LYVE-1/S100 stained section showing a group of melanoma cells impinging on the wall of a peritumorous lymphatic vessel (LYVE-1 stains red; S100 stains brown; original magnification, ×60).

Similar articles

Cited by

References

    1. Gerschenwald J, Thompson W, Mansfield P, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel node status in 612 stage I and II melanoma patients. J Clin Oncol 1999;3:976–83. - PubMed
    1. Wagner J, Corbett L, Myung Park H, et al. Sentinel lymph node biopsy for melanoma. Experience with 234 consecutive procedures. Plast Reconst Surg 2000;105:1956–66. - PubMed
    1. Landi G, Polverelli M, Moscatelli G, et al. Sentinel lymph node biopsy in patients with primary cutaneous melanoma; study of 455 cases. J Eur Acad Dermatol Venereol 2000;14:35–45. - PubMed
    1. Shivers S, Xang X, Li W, et al. Molecular staging of malignant melanoma. JAMA 1998;280:1410–15. - PubMed
    1. Blaheta H-J, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;14:637–42. - PubMed